Stock index futures rose on Friday, a day after Wall Street’s sell-off, while investors digested Amazon’s earnings results. Here are the four stocks to watch on the day:
Strategy (MSTR) shares jumped 9% in premarket trade even after the company posted Q4 2025 results. The bitcoin-focused firm reported a GAAP EPS of -$42.93, missing the -$20.99 analyst estimate, as unrealized losses on its bitcoin holdings overwhelmed a modest rise in software revenue. The loss widened significantly from -$3.03 in the year-ago quarter.
Pfizer (PFE) shares were flat before the opening bell after the company announced the U.S. Food and Drug Administration granted priority review for a marketing application seeking a label expansion for its hemophilia therapy, Hympavzi. The once-weekly subcutaneous injection is currently marketed in the U.S. for patients aged 12 years and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.
Hims & Hers Health (HIMS) shares fell ~7% in early action after FDA Commissioner Marty Makary said his agency will take swift action against “companies mass-marketing illegal copycat drugs.” The telehealth platform is well known for marketing compounded versions of Novo Nordisk’s weight-loss therapy semaglutide at a steep discount to the branded product.
Philip Morris (PM) shares slipped 2.4% in premarket trading after the tobacco giant reported mixed Q4 results. The company posted non-GAAP EPS of $1.70, in line with estimates, while revenue of $10.36 billion, up 6.7% year-over-year, missed expectations by $40 million. Philip Morris forecasts 2026 EPS of $7.87 to $8.02 with organic revenue growth of 5% to 7%.